MY203491A - Methods for the administration of certain vmat2 inhibitors - Google Patents

Methods for the administration of certain vmat2 inhibitors

Info

Publication number
MY203491A
MY203491A MYPI2019004294A MYPI2019004294A MY203491A MY 203491 A MY203491 A MY 203491A MY PI2019004294 A MYPI2019004294 A MY PI2019004294A MY PI2019004294 A MYPI2019004294 A MY PI2019004294A MY 203491 A MY203491 A MY 203491A
Authority
MY
Malaysia
Prior art keywords
methods
administration
vmat2 inhibitors
patient
certain
Prior art date
Application number
MYPI2019004294A
Other languages
English (en)
Inventor
Christopher F O'brien
Haig P Bozigian
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62978647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY203491(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of MY203491A publication Critical patent/MY203491A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Emergency Medicine (AREA)
MYPI2019004294A 2017-01-27 2017-10-10 Methods for the administration of certain vmat2 inhibitors MY203491A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762451605P 2017-01-27 2017-01-27
PCT/US2017/055980 WO2018140096A1 (en) 2017-01-27 2017-10-10 Methods for the administration of certain vmat2 inhibitors

Publications (1)

Publication Number Publication Date
MY203491A true MY203491A (en) 2024-06-30

Family

ID=62978647

Family Applications (5)

Application Number Title Priority Date Filing Date
MYPI2019004294A MY203491A (en) 2017-01-27 2017-10-10 Methods for the administration of certain vmat2 inhibitors
MYPI2020001816A MY202219A (en) 2017-01-27 2017-10-10 Methods for the administration of certain vmat2 inhibitors
MYPI2019004292A MY195934A (en) 2017-01-27 2017-10-10 Methods for the Administration of Certain VMAT2 Inhibitors
MYPI2019004296A MY199695A (en) 2017-01-27 2017-10-10 Methods for the administration of certain vmat2 inhibitors
MYPI2019004293A MY191077A (en) 2017-01-27 2017-10-10 Methods for the administration of certain vmat2 inhibitors

Family Applications After (4)

Application Number Title Priority Date Filing Date
MYPI2020001816A MY202219A (en) 2017-01-27 2017-10-10 Methods for the administration of certain vmat2 inhibitors
MYPI2019004292A MY195934A (en) 2017-01-27 2017-10-10 Methods for the Administration of Certain VMAT2 Inhibitors
MYPI2019004296A MY199695A (en) 2017-01-27 2017-10-10 Methods for the administration of certain vmat2 inhibitors
MYPI2019004293A MY191077A (en) 2017-01-27 2017-10-10 Methods for the administration of certain vmat2 inhibitors

Country Status (12)

Country Link
US (9) US20190381016A1 (enExample)
JP (16) JP7199361B2 (enExample)
KR (14) KR20190108147A (enExample)
CN (6) CN110740732A (enExample)
AU (7) AU2017395700B2 (enExample)
CA (5) CA3078719A1 (enExample)
EA (5) EA201991782A1 (enExample)
MX (6) MX394417B (enExample)
MY (5) MY203491A (enExample)
PH (6) PH12022553251A1 (enExample)
SG (3) SG11201906883SA (enExample)
WO (5) WO2018140093A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56137B1 (fr) 2015-10-30 2024-03-29 Neurocrine Biosciences Inc Sels de dihydrochlorure de valbénazine et leurs polymorphes
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
MY203491A (en) 2017-01-27 2024-06-30 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
PL3684333T3 (pl) 2017-09-21 2025-06-23 Neurocrine Biosciences, Inc. Formulacja walbenazyny o wysokiej dawce oraz kompozycje, sposoby i zestawy z nią związane
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
KR20250110361A (ko) 2017-10-10 2025-07-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3086611C (en) 2017-12-26 2023-07-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
IL278185B2 (en) 2018-04-25 2024-11-01 Shinkei Therapeutics Inc Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
US20200345663A1 (en) * 2018-06-10 2020-11-05 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion
MX2021001017A (es) * 2018-08-15 2021-04-19 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores de transportador vesicular de monoamina de proteinas transportadoras-2 (vmat2).
BR112021020709A2 (pt) * 2019-05-09 2021-12-14 Neurocrine Biosciences Inc Métodos para administração de certos inibidores de vmat2
CN114222576A (zh) * 2019-08-14 2022-03-22 F·霍夫曼-罗氏股份公司 治疗癌症的方法
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
KR20220119065A (ko) * 2019-12-20 2022-08-26 에자이 알앤드디 매니지먼트 가부시키가이샤 불면증 치료를 위한 렘보렉산트의 용도
AU2022302155A1 (en) 2021-06-30 2024-02-08 Neurocrine Biosciences, Inc. Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
WO2023278987A1 (en) 2021-06-30 2023-01-05 Neurocrine Biosciences, Inc. Valbenazine for use in the add-on treatment of schizophrenia
CA3228824A1 (en) * 2021-08-16 2023-02-23 Yuhua Li Polymer depot compositions for sustained release delivery of vmat2 inhibitors
US20250064990A1 (en) 2021-08-20 2025-02-27 Neurocrine Biosciences, Inc. Methods of screening for vmat2 inhibitors
EP4398893A4 (en) * 2021-09-10 2025-07-16 ATAI Life Sciences AG IBOGAINE COMBINATION THERAPY
JP2024540082A (ja) * 2021-10-29 2024-10-31 ニューロクライン バイオサイエンシーズ，インコーポレイテッド バルベナジン組成物
CA3245030A1 (en) 2022-03-07 2023-09-14 Neurocrine Biosciences Inc VALBENAZINE, A VMAT2 INHIBITOR, AS A FREE BASE OF A TOSYLATE OR DITOSYLATE SALT, INTENDED FOR USE IN THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
TW202430220A (zh) * 2022-11-16 2024-08-01 逸達生物科技股份有限公司 用於囊泡單胺轉運蛋白2 (vmat2) 抑制劑之補給型組合物
WO2025038959A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
TW202521119A (zh) 2023-08-17 2025-06-01 美商紐羅克里生物科學有限公司 用於投與特定vmat2抑制劑之方法
WO2025096823A1 (en) 2023-11-01 2025-05-08 Neurocrine Biosciences, Inc. Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
WO2025188830A1 (en) 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1068938A (en) 1910-11-07 1913-07-29 Gustav F Schulze Vehicle-apron.
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5283918A (en) 1976-01-01 1977-07-13 Wellcome Found Pharmaceutical composition
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5777697A (en) 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
JPS57209225A (en) 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
JPS6028987A (ja) 1983-07-28 1985-02-14 Chugai Pharmaceut Co Ltd 新規ジゴキシン誘導体
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
EP0835101B1 (en) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
KR100353304B1 (ko) 1996-10-01 2002-09-30 에스알아이 인터내셔널 맛이 차폐된 마이크로캡슐 조성물 및 이것의 제조 방법
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
DK0839525T3 (da) 1996-10-31 2004-11-29 Takeda Pharmaceutical Præparat med forlænget frigivelse
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
WO2000024399A1 (en) 1998-10-23 2000-05-04 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
JP2005527611A (ja) 2002-05-28 2005-09-15 ヘンリー エム．ジャクソン ファウンデーション フォー ジ アドバンスメント オブ ミリタリー メディシン、インク． 嚢胞性線維症およびその他のｉｌ−８依存性疾患治療用の強心配糖体
WO2004026258A2 (en) 2002-09-19 2004-04-01 University Of Utah Research Foundation Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease
US7230097B2 (en) 2003-03-10 2007-06-12 Lupin Ltd. Process for preparation of 7-[α-Amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid
GB0307259D0 (en) 2003-03-28 2003-05-07 Glaxo Group Ltd Process
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
KR20070029733A (ko) 2004-06-04 2007-03-14 제넨테크, 인크. 다발성 경화증의 치료 방법
CA3113166A1 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
DE602005011468D1 (de) 2004-10-28 2009-01-15 Wyeth Corp Gemeinsame gabe von tigecyclin und digoxin
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
ATE415968T1 (de) 2005-08-06 2008-12-15 Cambridge Lab Ireland Ltd 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
US20100076087A1 (en) 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
BRPI0718247B1 (pt) * 2006-11-08 2021-09-21 Neurocrine Biosciences, Inc. Composto usado como inibidor do transportador de monoamina vesicular 2, composição farmacêutica compreendendo o dito composto e uso da dita composição farmacêutica no tratamento de transtornos hipercinéticos
GB0721669D0 (en) 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
ES2548774T3 (es) 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
WO2011019956A2 (en) 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463452A (en) 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
LT3061760T (lt) 2008-09-18 2018-02-26 Auspex Pharmaceuticals, Inc. Deuterinti benzochinolizino dariniai kaip vezikuliarinio monoamino transporterio 2 slopikliai
US20100096319A1 (en) 2008-10-17 2010-04-22 General Electric Company Separator assembly
EP2417267B1 (en) * 2009-04-06 2016-08-17 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012153341A1 (en) 2011-05-12 2012-11-15 Arch Pharmalabs Limited A process for the preparation of iloperidone and pharmaceutically acceptable salts thereof
NZ705372A (en) * 2012-09-18 2018-07-27 Auspex Pharmaceuticals Inc Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
KR20170058464A (ko) * 2012-12-18 2017-05-26 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
MX2015009719A (es) 2013-01-31 2016-08-08 Auspex Pharmaceuticals Inc Inhibidores benzoquinolona de vmat2.
WO2015077521A1 (en) * 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
MX2016009817A (es) * 2014-01-27 2017-02-28 Auspex Pharmaceuticals Inc Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
US9782398B2 (en) 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
CN112741835A (zh) 2014-05-06 2021-05-04 纽罗克里生物科学有限公司 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂
WO2016127133A1 (en) 2015-02-06 2016-08-11 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
DK3265085T3 (da) 2015-03-06 2022-10-03 Auspex Pharmaceuticals Inc Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser
MY189806A (en) 2015-06-23 2022-03-08 Neurocrine Biosciences Inc Vmat2 inhibitors for treating neurological diseases or disorders
MA56137B1 (fr) 2015-10-30 2024-03-29 Neurocrine Biosciences Inc Sels de dihydrochlorure de valbénazine et leurs polymorphes
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
TW201827051A (zh) 2016-12-02 2018-08-01 美商神經性分泌生物科學公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
MY203491A (en) 2017-01-27 2024-06-30 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
RU2768738C2 (ru) 2017-04-01 2022-03-24 Адептио Фармасьютикалз Лимитед ПРИМЕНЕНИЕ (-)-α-ДИГИДРОТЕТРАБЕНАЗИНА ИЛИ ЕГО КОМБИНАЦИИ С (+)-α-ДИГИДРОТЕТРАБЕНАЗИНОМ В ЛЕЧЕНИИ ГИПЕРКИНЕТИЧЕСКОГО ДВИГАТЕЛЬНОГО РАССТРОЙСТВА, А ТАКЖЕ СООТВЕТСТВУЮЩИЕ СПОСОБЫ
CN110678181A (zh) 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
US10376507B2 (en) * 2017-05-16 2019-08-13 Bow River LLC Method of treating a patient with a CYP3A4 substrate drug
US10857144B2 (en) * 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
PL3684333T3 (pl) 2017-09-21 2025-06-23 Neurocrine Biosciences, Inc. Formulacja walbenazyny o wysokiej dawce oraz kompozycje, sposoby i zestawy z nią związane
KR20250110361A (ko) 2017-10-10 2025-07-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US11384077B2 (en) 2017-11-22 2022-07-12 Assia Chemical Industries Ltd. Solid state form of Valbenazine
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
MX2021001017A (es) 2018-08-15 2021-04-19 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores de transportador vesicular de monoamina de proteinas transportadoras-2 (vmat2).
BR112021020709A2 (pt) 2019-05-09 2021-12-14 Neurocrine Biosciences Inc Métodos para administração de certos inibidores de vmat2
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Also Published As

Publication number Publication date
CN110769826A (zh) 2020-02-07
JP7090151B2 (ja) 2022-06-23
PH12019501734A1 (en) 2020-07-06
KR20230170136A (ko) 2023-12-18
PH12022553251A1 (en) 2024-05-20
CN116712434A (zh) 2023-09-08
MX393077B (es) 2025-03-24
EA201991784A1 (ru) 2021-09-23
MX2019008854A (es) 2019-09-11
EA201991786A1 (ru) 2020-01-16
KR20190108146A (ko) 2019-09-23
SG11201906885TA (en) 2019-08-27
PH12019501744A1 (en) 2019-09-30
PH12020550238A1 (en) 2021-02-15
WO2018140096A1 (en) 2018-08-02
KR20200126430A (ko) 2020-11-06
AU2017395703B2 (en) 2021-09-23
KR20250020722A (ko) 2025-02-11
US20200268743A1 (en) 2020-08-27
SG11201906883SA (en) 2019-08-27
WO2018140092A1 (en) 2018-08-02
WO2018140093A1 (en) 2018-08-02
CA3051834C (en) 2024-05-28
JP2020505408A (ja) 2020-02-20
KR20190108148A (ko) 2019-09-23
KR20230169457A (ko) 2023-12-15
AU2017395704B2 (en) 2022-02-24
CA3051832C (en) 2024-05-28
JP2022040408A (ja) 2022-03-10
JP2022174344A (ja) 2022-11-22
US10912771B1 (en) 2021-02-09
US11040029B2 (en) 2021-06-22
JP2024107168A (ja) 2024-08-08
MY191077A (en) 2022-05-30
JP2022174345A (ja) 2022-11-22
AU2017395704B8 (en) 2022-03-17
JP2020514317A (ja) 2020-05-21
WO2018140094A1 (en) 2018-08-02
PH12019501732A1 (en) 2020-03-16
US20190381016A1 (en) 2019-12-19
CN110740732A (zh) 2020-01-31
US10874648B2 (en) 2020-12-29
CA3051830A1 (en) 2018-08-02
AU2017395703A1 (en) 2019-08-22
AU2017395704A8 (en) 2022-03-17
KR20230038601A (ko) 2023-03-20
MX2022007141A (es) 2022-07-19
JP7199359B2 (ja) 2023-01-05
JP2020536905A (ja) 2020-12-17
JP2024113134A (ja) 2024-08-21
JP2023161033A (ja) 2023-11-02
MY195934A (en) 2023-02-27
KR20190108147A (ko) 2019-09-23
KR20190108149A (ko) 2019-09-23
KR20250022883A (ko) 2025-02-17
JP2020505407A (ja) 2020-02-20
MX2020003462A (es) 2020-08-03
MX394418B (es) 2025-03-24
US10857137B2 (en) 2020-12-08
CA3051832A1 (en) 2018-08-02
CN110740731A (zh) 2020-01-31
PH12019501740A1 (en) 2019-10-07
JP2022137219A (ja) 2022-09-21
US20200268725A1 (en) 2020-08-27
KR20250078629A (ko) 2025-06-02
CN110709071A (zh) 2020-01-17
US20210169862A1 (en) 2021-06-10
EA202090676A1 (ru) 2021-10-08
US10952997B2 (en) 2021-03-23
JP2024107169A (ja) 2024-08-08
KR20200066662A (ko) 2020-06-10
JP7199361B2 (ja) 2023-01-05
MX2019008868A (es) 2019-09-16
JP2020514318A (ja) 2020-05-21
JP2022174343A (ja) 2022-11-22
CA3051829A1 (en) 2018-08-02
MX2019008853A (es) 2019-09-11
CA3051834A1 (en) 2018-08-02
US20200093808A1 (en) 2020-03-26
US20210030742A1 (en) 2021-02-04
WO2018140095A3 (en) 2018-11-29
SG11201906891RA (en) 2019-08-27
JP2024107167A (ja) 2024-08-08
KR20230170135A (ko) 2023-12-18
CN111655034A (zh) 2020-09-11
US20200338066A1 (en) 2020-10-29
MY199695A (en) 2023-11-18
CA3078719A1 (en) 2018-08-02
AU2022203201B2 (en) 2023-11-02
AU2017395701B2 (en) 2024-02-15
AU2017395702A1 (en) 2019-08-22
MX2019008855A (es) 2019-09-11
KR20250020723A (ko) 2025-02-11
AU2017395704A1 (en) 2019-08-22
JP7199360B2 (ja) 2023-01-05
WO2018140095A2 (en) 2018-08-02
MY202219A (en) 2024-04-17
AU2017395700A1 (en) 2019-08-22
JP2025146959A (ja) 2025-10-03
MX394417B (es) 2025-03-24
AU2017395700B2 (en) 2022-02-24
AU2017395701A1 (en) 2020-06-18
JP7107950B2 (ja) 2022-07-27
AU2022203327A1 (en) 2022-06-09
EA201991780A1 (ru) 2021-10-26
US20210046060A1 (en) 2021-02-18
AU2022203201A1 (en) 2022-06-02
US20200268724A1 (en) 2020-08-27
MX394415B (es) 2025-03-24
US11439629B2 (en) 2022-09-13
AU2017395702B2 (en) 2021-09-09
EA201991782A1 (ru) 2021-09-23

Similar Documents

Publication Publication Date Title
MY203491A (en) Methods for the administration of certain vmat2 inhibitors
PH12020550237A1 (en) Methods for the administration of certain vmat2 inhibitors
PH12021550302A1 (en) Methods for the administration of certain vmat2 inhibitors
MX2023012361A (es) Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
ZA202007681B (en) Pharmaceutical combination, composition and combination formulation comprising glucokinase activator and dpp-iv inhibitor, and preparation method and use thereof
ZA201902053B (en) Pharmaceutical composition
EA038122B9 (ru) Ингибитор поверхностного антигена вируса гепатита b
WO2016133903A3 (en) Combination therapy for cancer treatment
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
WO2018086589A8 (zh) 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
NZ712584A (en) Antitumor agent including irinotecan hydrochloride hydrate
EA202190252A1 (ru) Способы введения определенных ингибиторов vmat2
MX389403B (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo
MY199579A (en) New use of isoquinoline derivatives for diabetic wound healing
MY203919A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
UA109242U (uk) Стабільна фармацевтична композиція, що містить інгібітор протеасом
UA99621U (uk) Спосіб лікування хронічного біліарного панкреатиту